Teva Pharmaceutical Industries Limited (TEVA) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Teva Pharmaceutical Industries Limited (TEVA) Bundle
Engineered for accuracy, our Teva Pharmaceutical Industries Limited (TEVA) DCF Calculator enables you to assess the valuation of Teva with comprehensive financial data and complete flexibility to modify all essential parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16,887.0 | 16,658.0 | 15,878.0 | 14,925.0 | 15,846.0 | 15,613.5 | 15,384.4 | 15,158.6 | 14,936.2 | 14,717.0 |
| Revenue Growth, % | 0 | -1.36 | -4.68 | -6 | 6.17 | -1.47 | -1.47 | -1.47 | -1.47 | -1.47 |
| EBITDA | 1,279.0 | -2,094.0 | 4,409.0 | -874.0 | 1,570.0 | 837.6 | 825.3 | 813.2 | 801.3 | 789.5 |
| EBITDA, % | 7.57 | -12.57 | 27.77 | -5.86 | 9.91 | 5.36 | 5.36 | 5.36 | 5.36 | 5.36 |
| Depreciation | 1,722.0 | 1,557.0 | 1,330.0 | 1,308.0 | 1,153.0 | 1,372.8 | 1,352.6 | 1,332.8 | 1,313.2 | 1,293.9 |
| Depreciation, % | 10.2 | 9.35 | 8.38 | 8.76 | 7.28 | 8.79 | 8.79 | 8.79 | 8.79 | 8.79 |
| EBIT | -443.0 | -3,651.0 | 3,079.0 | -2,182.0 | 417.0 | -535.1 | -527.3 | -519.6 | -511.9 | -504.4 |
| EBIT, % | -2.62 | -21.92 | 19.39 | -14.62 | 2.63 | -3.43 | -3.43 | -3.43 | -3.43 | -3.43 |
| Total Cash | 1,975.0 | 2,177.0 | 2,165.0 | 2,801.0 | 3,226.0 | 2,420.9 | 2,385.3 | 2,350.3 | 2,315.9 | 2,281.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5,676.0 | 4,581.0 | 4,529.0 | 3,696.0 | 3,408.0 | 4,243.9 | 4,181.7 | 4,120.3 | 4,059.8 | 4,000.3 |
| Account Receivables, % | 33.61 | 27.5 | 28.52 | 24.76 | 21.51 | 27.18 | 27.18 | 27.18 | 27.18 | 27.18 |
| Inventories | 4,422.0 | 4,403.0 | 3,818.0 | 3,833.0 | 4,021.0 | 3,988.3 | 3,929.8 | 3,872.1 | 3,815.3 | 3,759.3 |
| Inventories, % | 26.19 | 26.43 | 24.05 | 25.68 | 25.38 | 25.54 | 25.54 | 25.54 | 25.54 | 25.54 |
| Accounts Payable | 1,718.0 | 1,756.0 | 1,686.0 | 1,887.0 | 2,602.0 | 1,886.0 | 1,858.3 | 1,831.1 | 1,804.2 | 1,777.7 |
| Accounts Payable, % | 10.17 | 10.54 | 10.62 | 12.64 | 16.42 | 12.08 | 12.08 | 12.08 | 12.08 | 12.08 |
| Capital Expenditure | -119.0 | -578.0 | -562.0 | -548.0 | -526.0 | -459.2 | -452.5 | -445.8 | -439.3 | -432.8 |
| Capital Expenditure, % | -0.70468 | -3.47 | -3.54 | -3.67 | -3.32 | -2.94 | -2.94 | -2.94 | -2.94 | -2.94 |
| Tax Rate, % | 10.42 | 10.42 | 10.42 | 10.42 | 10.42 | 10.42 | 10.42 | 10.42 | 10.42 | 10.42 |
| EBITAT | -349.8 | -3,306.3 | 1,951.3 | -1,675.1 | 373.6 | -427.3 | -421.1 | -414.9 | -408.8 | -402.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -7,126.8 | -1,175.3 | 3,286.3 | 103.9 | 1,815.6 | -1,033.0 | 572.2 | 563.8 | 555.6 | 547.4 |
| WACC, % | 6.32 | 6.55 | 6.02 | 6.28 | 6.53 | 6.34 | 6.34 | 6.34 | 6.34 | 6.34 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 840.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 558 | |||||||||
| Terminal Value | 12,860 | |||||||||
| Present Terminal Value | 9,457 | |||||||||
| Enterprise Value | 10,297 | |||||||||
| Net Debt | 16,927 | |||||||||
| Equity Value | -6,630 | |||||||||
| Diluted Shares Outstanding, MM | 1,119 | |||||||||
| Equity Value Per Share | -5.92 |
What You Will Get
- Real Teva Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Teva’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical performance and future forecasts for Teva Pharmaceutical Industries Limited (TEVA).
- Adjustable Forecast Parameters: Modify yellow-highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Enjoy automatic updates to DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Utilize clear charts and summaries to easily interpret your valuation outcomes.
- Designed for All Levels: A straightforward, intuitive layout tailored for investors, CFOs, and consultants alike.
How It Works
- Download: Obtain the pre-configured Excel file containing Teva Pharmaceutical Industries Limited's (TEVA) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly compare the results.
- Make Decisions: Leverage the valuation outcomes to inform your investment choices.
Why Choose This Calculator for Teva Pharmaceutical Industries Limited (TEVA)?
- Accurate Data: Real Teva financials ensure dependable valuation outcomes.
- Customizable: Modify key metrics such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-built calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: Intuitive design and step-by-step guidance make it accessible for all users.
Who Should Use Teva Pharmaceutical Industries Limited (TEVA)?
- Investors: Gain insights and make informed decisions with a reliable evaluation of Teva's market position.
- Financial Analysts: Utilize comprehensive financial data to streamline your analysis of Teva's performance.
- Consultants: Tailor your presentations or reports efficiently with Teva's industry-specific information.
- Pharmaceutical Professionals: Enhance your knowledge of the pharmaceutical sector by studying Teva's strategies and operations.
- Educators and Students: Leverage real-world case studies of Teva in academic discussions and projects.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Teva Pharmaceutical historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Teva Pharmaceutical Industries Limited (TEVA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.